ActiQs / Forskning

PUBLIKATIONSREGISTRET

Gå till forskningen.

Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.

Publikationer som ChEBI hänvisar till för tanespimycin. Visa hela publikationsregistret

En publikationsträff är inte en slutsats. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.

Publikationer i urvalet

27 träffar

Bibliografisk träff 2016-06-01

Acquired resistance to HSP90 inhibitor 17-AAG and increased metastatic potential are associated with MUC1 expression in colon carcinoma cells.

Liu X, Ban LL, Luo G, Li ZY, Li YF, Zhou YC, Wang XC, Jin CG, Ye JG, Ma DD, Xie Q, Huang YG.

Anticancer Drugs · research support, non-u.s. gov't; journal article · DOI 10.1097/cad.0000000000000347

Bibliografisk träff 2016-04-05

NAD(P)H:Quinone Oxidoreductase-1 Expression Sensitizes Malignant Melanoma Cells to the HSP90 Inhibitor 17-AAG.

Kasai S, Arakawa N, Okubo A, Shigeeda W, Yasuhira S, Masuda T, Akasaka T, Shibazaki M, Maesawa C.

PLoS One · research support, non-u.s. gov't; research-article; journal article · DOI 10.1371/journal.pone.0153181

Bibliografisk träff 2016-02-01

[HSP90 Inhibitor 17-AAG Inhibits Multiple Myeloma Cell Proliferation by Down-regulating Wnt/β-Catenin Signaling Pathway].

Chen KK, He ZM, Ding BH, Chen Y, Zhang LJ, Yu L, Gao J.

Zhongguo Shi Yan Xue Ye Xue Za Zhi · journal article · DOI 10.7534/j.issn.1009-2137.2016.01.023

Bibliografisk träff 2015-12-01

17-(allylamino)-17-demethoxygeldanamycin drives Hsp70 expression but fails to improve morphological or functional recovery in injured skeletal muscle.

Baumann CW, Otis JS.

Clin Exp Pharmacol Physiol · journal article · DOI 10.1111/1440-1681.12477

Bibliografisk träff 2015-10-01

17-Allylamino-17-demethoxygeldanamycin and Herbimycin A Induce Cell Death by Modulating β-Catenin and PI3K/AKT Signaling in FRO Anaplastic Thyroid Carcinoma Cells.

Kim SH, Kang JG, Kim CS, Ihm SH, Choi MG, Yoo HJ, Lee SJ.

Anticancer Res · research support, non-u.s. gov't; journal article

Bibliografisk träff 2015-09-11

The heat shock protein 90 inhibitor, 17-AAG, attenuates thioacetamide induced liver fibrosis in mice.

Abu-Elsaad NM, Serrya MS, El-Karef AM, Ibrahim TM.

Pharmacol Rep · journal article · DOI 10.1016/j.pharep.2015.08.015

Bibliografisk träff 2015-09-01

17-Allylamino-17-Demethoxygeldanamycin and the Enhancement of PS-341-Induced Lung Cancer Cell Death by Blocking the NF-κB and PI3K/Akt Pathways.

Lee KH, Jang AH, Yoo CG.

Am J Respir Cell Mol Biol · research support, non-u.s. gov't; journal article · DOI 10.1165/rcmb.2014-0186oc

Bibliografisk träff 2015-05-08

Phase II trial of gemcitabine and tanespimycin (17AAG) in metastatic pancreatic cancer: a Mayo Clinic Phase II Consortium study.

Pedersen KS, Kim GP, Foster NR, Wang-Gillam A, Erlichman C, McWilliams RR.

Invest New Drugs · clinical trial, phase ii; research-article; multicenter study; journal article; research support, n.i.h., extramural · DOI 10.1007/s10637-015-0246-2

Bibliografisk träff 2014-08-06

The effect of 17-allylamino-17-demethoxygeldanamycin alone or in combination with paclitaxel on anaplastic thyroid carcinoma cells.

Kim SH, Kang JG, Kim CS, Ihm SH, Choi MG, Yoo HJ, Lee SJ.

Endocrine · research support, non-u.s. gov't; journal article · DOI 10.1007/s12020-014-0371-2

Bibliografisk träff 2013-12-05

The HSP90 inhibitor 17-N-allylamino-17-demethoxy geldanamycin (17-AAG) synergizes with cisplatin and induces apoptosis in cisplatin-resistant esophageal squamous cell carcinoma cell lines via the Akt/XIAP pathway.

Ui T, Morishima K, Saito S, Sakuma Y, Fujii H, Hosoya Y, Ishikawa S, Aburatani H, Fukayama M, Niki T, Yasuda Y.

Oncol Rep · journal article · DOI 10.3892/or.2013.2899

Bibliografisk träff 2013-04-06

Open-label, dose-escalation, safety, pharmacokinetic, and pharmacodynamic study of intravenously administered CNF1010 (17-(allylamino)-17-demethoxygeldanamycin [17-AAG]) in patients with solid tumors.

Saif MW, Erlichman C, Dragovich T, Mendelson D, Toft D, Burrows F, Storgard C, Von Hoff D.

Cancer Chemother Pharmacol · research support, non-u.s. gov't; clinical trial, phase i; journal article · DOI 10.1007/s00280-013-2134-9

Bibliografisk träff 2012-05-23

Effects of HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin (17-AAG) on NEU/HER2 overexpressing mammary tumours in MMTV-NEU-NT mice monitored by Magnetic Resonance Spectroscopy.

Rodrigues LM, Chung YL, Al Saffar NM, Sharp SY, Jackson LE, Banerji U, Stubbs M, Leach MO, Griffiths JR, Workman P.

BMC Res Notes · research support, non-u.s. gov't; research-article; journal article · DOI 10.1186/1756-0500-5-250

Bibliografisk träff 2012-02-10

Folate receptor targeted 17-allylamino-17-demethoxygeldanamycin (17-AAG) loaded polymeric nanoparticles for breast cancer.

Saxena V, Naguib Y, Hussain MD.

Colloids Surf B Biointerfaces · journal article · DOI 10.1016/j.colsurfb.2012.02.001

Bibliografisk träff 2011-12-31

Tipifarnib and tanespimycin show synergic proapoptotic activity in U937 cells.

Krzykowska-Petitjean K, Małecki J, Bentke A, Ostrowska B, Laidler P.

J Cancer Res Clin Oncol · brief-report; research support, non-u.s. gov't; journal article · DOI 10.1007/s00432-011-1131-9

Bibliografisk träff 2011-11-01

A phase II study of gemcitabine in combination with tanespimycin in advanced epithelial ovarian and primary peritoneal carcinoma.

Hendrickson AE, Oberg AL, Glaser G, Camoriano JK, Peethambaram PP, Colon-Otero G, Erlichman C, Ivy SP, Kaufmann SH, Karnitz LM, Haluska P.

Gynecol Oncol · clinical trial, phase ii; research-article; journal article; research support, n.i.h., extramural · DOI 10.1016/j.ygyno.2011.10.002

Bibliografisk träff 2011-08-12

Synthesis and evaluation of poly(styrene-co-maleic acid) micellar nanocarriers for the delivery of tanespimycin.

Larson N, Greish K, Bauer H, Maeda H, Ghandehari H.

Int J Pharm · research-article; journal article; research support, n.i.h., extramural · DOI 10.1016/j.ijpharm.2011.08.011

Bibliografisk träff 2011-07-26

Phase I and pharmacological study of cytarabine and tanespimycin in relapsed and refractory acute leukemia.

Kaufmann SH, Karp JE, Litzow MR, Mesa RA, Hogan W, Steensma DP, Flatten KS, Loegering DA, Schneider PA, Peterson KL, Maurer MJ, Smith BD, Greer J, Chen Y, Reid JM, Ivy SP, Ames MM, Adjei AA, Erlichman C, Karnitz LM.

Haematologica · research support, non-u.s. gov't; research-article; multicenter study; clinical trial, phase i; journal article; research support, n.i.h., extramural · DOI 10.3324/haematol.2011.049551

Bibliografisk träff 2011-06-13

Why is this effective HSP90 inhibitor not being developed in HER2+ breast cancer?

Arteaga CL.

Clin Cancer Res · comment; research support, non-u.s. gov't; research-article; journal article; research support, n.i.h., extramural · DOI 10.1158/1078-0432.ccr-11-1218

Bibliografisk träff 2011-05-19

In vitro assessment of cytochrome P450 inhibition and induction potential of tanespimycin and its major metabolite, 17-amino-17-demethoxygeldanamycin.

Gan J, Liu-Kreyche P, Humphreys WG.

Cancer Chemother Pharmacol · journal article · DOI 10.1007/s00280-011-1672-2

Bibliografisk träff 2011-05-10

HSP90 inhibition is effective in breast cancer: a phase II trial of tanespimycin (17-AAG) plus trastuzumab in patients with HER2-positive metastatic breast cancer progressing on trastuzumab.

Modi S, Stopeck A, Linden H, Solit D, Chandarlapaty S, Rosen N, D'Andrea G, Dickler M, Moynahan ME, Sugarman S, Ma W, Patil S, Norton L, Hannah AL, Hudis C.

Clin Cancer Res · clinical trial, phase ii; research support, non-u.s. gov't; journal article · DOI 10.1158/1078-0432.ccr-11-0072

Bibliografisk träff 2011-04-28

Tanespimycin and bortezomib combination treatment in patients with relapsed or relapsed and refractory multiple myeloma: results of a phase 1/2 study.

Richardson PG, Chanan-Khan AA, Lonial S, Krishnan AY, Carroll MP, Alsina M, Albitar M, Berman D, Messina M, Anderson KC.

Br J Haematol · clinical trial, phase ii; research support, non-u.s. gov't; multicenter study; clinical trial, phase i; journal article · DOI 10.1111/j.1365-2141.2011.08664.x

Bibliografisk träff 2011-02-01

Tanespimycin as antitumor therapy.

Dimopoulos MA, Mitsiades CS, Anderson KC, Richardson PG.

Clin Lymphoma Myeloma Leuk · research support, non-u.s. gov't; review; journal article · DOI 10.3816/clml.2011.n.002

Bibliografisk träff 2011-01-21

Expression-based in silico screening of candidate therapeutic compounds for lung adenocarcinoma.

Wang G, Ye Y, Yang X, Liao H, Zhao C, Liang S.

PLoS One · research support, non-u.s. gov't; research-article; journal article · DOI 10.1371/journal.pone.0014573

Bibliografisk träff 2011-01-10

Inhibition of heat shock protein 90 (HSP90) as a therapeutic strategy for the treatment of myeloma and other cancers.

Richardson PG, Mitsiades CS, Laubach JP, Lonial S, Chanan-Khan AA, Anderson KC.

Br J Haematol · research support, non-u.s. gov't; review; journal article · DOI 10.1111/j.1365-2141.2010.08360.x

Bibliografisk träff 2010-08-05

A Phase II trial of 17-allylamino, 17-demethoxygeldanamycin (17-AAG, tanespimycin) in patients with metastatic melanoma.

Pacey S, Gore M, Chao D, Banerji U, Larkin J, Sarker S, Owen K, Asad Y, Raynaud F, Walton M, Judson I, Workman P, Eisen T.

Invest New Drugs · clinical trial, phase ii; research support, non-u.s. gov't; multicenter study; journal article · DOI 10.1007/s10637-010-9493-4

Bibliografisk träff 2010-07-23

Tanespimycin pharmacokinetics: a randomized dose-escalation crossover phase 1 study of two formulations.

Burris HA, Berman D, Murthy B, Jones S.

Cancer Chemother Pharmacol · comparative study; research support, non-u.s. gov't; clinical trial, phase i; randomized controlled trial; journal article · DOI 10.1007/s00280-010-1398-6

Bibliografisk träff 2010-06-19

17-N-Allylamino-17-demethoxygeldanamycin induces a diverse response in human acute myelogenous cells.

Napper JM, Sollars VE.

Leuk Res · research-article; research support, u.s. gov't, non-p.h.s.; journal article; research support, n.i.h., extramural · DOI 10.1016/j.leukres.2010.05.024